Jesse McClain
Adult Health · Youngstown, OHNPI 1396891792
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,333 of the $78,971 with a category attached, or 90.3%. AbbVie accounts for 95.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $31,728 and has fallen 87.7% since, to $3,894 in 2025. Among adult health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $247.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$75K
- Livanova USA, Inc.$1K
- Biogen$680
- E.r. Squibb & Sons, L.L.C.$339
- Amgen$263
- SK Life Science, Inc.$261
- plus $974 from 18 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$71,33390%
- Travel & lodging$2,0243%
- Food & beverage$5,2807%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 227 | $74,991 |
| Livanova USA, Inc. | 9 | $1,462 |
| Biogen | 24 | $680 |
| E.r. Squibb & Sons, L.L.C. | 3 | $339 |
| Amgen | 12 | $263 |
| SK Life Science, Inc. | 10 | $261 |
| Sanofi | 5 | $163 |
| Abbott | 1 | $136 |
| UCB, Inc. | 3 | $100 |
| Johnson & Johnson(2 entities) | 3 | $73 |
| Argenx US, Inc. | 1 | $70 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Cala Health, Inc. | 1 | $43 |
| Genentech USA, Inc. | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| AstraZeneca | 1 | $34 |
| Pfizer | 1 | $28 |
| EMD Serono, Inc. | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$59,332
- QULIPTA$20,423
- VNS Therapy$1,261
- ZEPOSIA$339
- TYSABRI$300
- AIMOVIG$180
- AMPLATZER TALISMAN$136
- VNS - Sentiva$128
- AUBAGIO$120
How this compares
$78,971 in reported general payments places this provider in the 95th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 30 | $327,871 |
| Radicava OrsEdaravone | 22 | $310,950 |
| Kesimpta PenOfatumumab | 25 | $214,212 |
| TecfideraDimethyl Fumarate | 21 | $183,270 |
| BriviactBrivaracetam | 71 | $101,228 |
| TysabriNatalizumab | 12 | $97,606 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $95,342 |
| MestinonPyridostigmine Bromide | 17 | $92,842 |
| AptiomEslicarbazepine Acetate | 61 | $84,452 |
| NeuproRotigotine | 51 | $73,234 |
| QuliptaAtogepant | 54 | $67,710 |
| AustedoDeutetrabenazine | 14 | $67,238 |
| Lacosamide | 346 | $45,457 |
| XcopriCenobamate | 34 | $41,591 |
| Nurtec OdtRimegepant Sulfate | 22 | $41,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $43 | $395,10844 claims |
| BiogenTecfidera, Tysabri | $680 | $280,87633 claims |
| UCB, Inc.Briviact, Neupro, Vimpat, Nayzilam | $100 | $212,655152 claims |
| AbbVieQulipta, Ubrelvy | $74,991 | $106,08576 claims |
| SK Life Science, Inc.Xcopri | $261 | $41,59134 claims |
| PfizerNurtec Odt | $28 | $41,36722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,184 adult health providers in Ohio.
Other adult health in Youngstown
- Frances ClarkYoungstown$18K
- Deborah NicholsYoungstown$8K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Teresa ShafferBoardman$102K
- Lucretia LongColumbus$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.